Not Yet Recruiting PHASE4 INTERVENTIONAL 2-arm NCT07103655

The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction (BRAVE-HCM)

The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction: A Prospective, Interventional, Real-World Clinical Study.

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Conditions Hypertrophic Cardiomyopathy (HCM)

Interventions Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol diltiazem mavacamten

Updated 2 times since 2025 Last updated: Jan 19, 2026 Started: Jan 1, 2026 Primary completion: Jul 1, 2026 Completion: Jan 1, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Hypertrophic Cardiomyopathy (HCM) and is currently actively recruiting participants. Second Affiliated Hospital, School of Medicine, Zhejiang University leads this study, which shows 2 recorded versions since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

2 versions recorded

Feb 2026 — Present [monthly]

Not Yet Recruiting PHASE4
Sep 2025 — Feb 2026 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Second Affiliated Hospital, School of Medicine, Zhejiang University

Data source: Second Affiliated Hospital, School of Medicine, Zhejiang University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China